On July 9, 2025, Enhalor convened its flagship Mid-Year Summit in Dalian, bringing together marketing representatives from across China. The summit featured a comprehensive review of the company's first-half business performance, including a thorough analysis of market dynamics and operational achievements, while simultaneously charting a clear strategic course for Enhalor's long-term development trajectory.

Chairman's Address

During the summit, Dr. Ren Zelin, Chairman of Enhalor, delivered a flagship address entitled 'Navigating the Present, Embracing the Future with Confidence.' In his presentation, Dr. Ren charted a forward-looking strategic blueprint centered on three key pillars: product innovation, customer engagement, and global expansion. He emphasized that synthetic biology would be the focal point of the company's R&D initiatives, with Enhalor poised to build a differentiated competitive edge through targeted investments in this field. Regarding internationalization strategy, the company will proactively pursue deep collaborations with global industry leaders, leveraging the vast global marketplace to drive sustainable growth and achieve breakthrough innovation.

The first half of 2025 saw Enhalor achieve stellar sales performance marked by exceptional momentum, with total revenue surging 41% year-on-year to surpass all historical records. This outstanding commercial achievement, coupled with significant progress in customer acquisition, has laid robust groundwork for continued expansion of the company's market footprint.

Notably, Enhalor has consistently maintained its pioneering position in the global marketplace. The company's innovative biotech products—celebrated for exceptional production performance and demonstrated health benefits—now reach over 90 countries and territories across Europe, North America, and beyond. International sales surged dramatically, achieving 93.8% year-on-year growth. Moving forward, guided by its philosophy of 'Relentless Excellence in Delivering Value and Enhanced Welfare for Global Partners,' Enhalor will leverage cutting-edge biotechnology to advance sustainable development in animal nutrition and health worldwide, contributing innovative solutions to the industry.

ENHALOR

Founded in 2000 at the Chinese Academy of Agricultural Sciences, Enhalor has established deep expertise in molecular biotechnology with a dedicated focus on animal nutrition and health. Through strategic R&D partnerships with leading institutions including the Institute of Microbiology (Chinese Academy of Sciences), Tsinghua University, and Ocean University of China, the company has pioneered a portfolio of innovative biotech products—such as yeast parabiotics, functional peptides, and bio-emulsifiers. These scientifically advanced solutions, recognized for superior production performance and proven health benefits, now serve major global markets across 90+ countries and territories in Europe, North America, and beyond.

Guided by its core philosophy of 'Relentless Excellence in Delivering Partner Value and Enhanced Welfare,' Enhalor continues to advance sustainable innovation in animal nutrition through cutting-edge biotechnology.